BridgeBio Pharma, Inc. (BBIO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 25.03 |
| Open | 25.37 |
| Bid | 24.32 x 200 |
| Ask | 24.35 x 200 |
| Day's range | 23.68 - 24.50 |
| 52-week range | 12.75 - 44.32 |
| Volume | |
| Avg. volume | 1,711,170 |
| Market cap | 4.488B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
- Investor's Business Daily
BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.
© 2024 Yahoo. All rights reserved.